Economic burden of herpes zoster among skilled nursing facility residents in the United States

Journal of the American Medical Directors Association

Volumn 13, Issue 1, 2012, Pages 54-59

  Ma, Liyuan ^a   White, Ronald R ^a   Narayanan, Siva ^b   Schmader, Kenneth E ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b TNS Healthcare   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HERPES ZOSTER; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NURSING HOME; POSTHERPETIC NEURALGIA; PROPENSITY SCORE; RETROSPECTIVE STUDY;

EID: 84855178245     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2010.03.015     Document Type: Article

References (30)

1. Dworkin R.H., Johnson R.W., Breuer J., et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44(Suppl 1):S1-26.
2. Gnann J.W., Whitley R.J. Clinical practice. Herpes zoster. NEngl J Med 2002, 347(5):340-346.
3. Johnson R.W. Consequences and management of pain in herpes zoster. JInfect Dis 2002, 186(Suppl 1):S83-S90.
4. Yawn B.P., Saddier P., Wollan P.C., et al. Apopulation-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82(11):1341-1349.
5. Oxman M.N., Levin M.J., Johnson G.R., et al. Avaccine to prevent herpes zoster and postherpetic neuralgia in older adults. NEngl J Med 2005, 352(22):2271-2284.
6. Donahue J.G., Choo P.W., Manson J.E., et al. The incidence of herpes zoster. Arch Intern Med 1995, 155(15):1605-1609.
7. Insinga R.P., Itzler R.F., Pellissier J.M., et al. The incidence of herpes zoster in a United States administrative database. JGen Intern Med 2005, 20(8):748-753.
8. Edmunds W.J., Brisson M., Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001, 19(23-24):3076-3090.
9. Hope-Simpson R.E. Postherpetic neuralgia. JR Coll Gen Pract 1975, 25(157):571-575.
10. Choo P.W., Galil K., Donahue J.G., et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997, 157(11):1217-1224.
11. Oster G., Harding G., Dukes E., et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey. JPain 2005, 6(6):356-363.
12. Schmader K.E., Sloane R., Pieper C., et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007, 23(6):490-496.
13. Lieu T.A., Ortega-Sanchez I., Ray G.T., et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008, 26(3):235-249.
14. Coplan P., Black S., Rojas C., et al. Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: A baseline assessment of the shifting epidemiology of varicella disease. Pediatr Infect Dis J 2001, 20(7):641-645.
15. Insinga R.P., Itzler R.F., Pellissier J.M. Acute/subacute herpes zoster: Healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007, 25(2):155-169.
16. White R.R., Lenhart G., Singhal P.K., et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics 2009, 27(9):781-792.
17. Dworkin R.H., White R., O'Connor A.B., et al. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. JAm Geriatr Soc 2007, 55(8):1168-1175.
18. Schmader K.E. Herpes zoster in the long-term setting. Ann Long Term Care 2004, 12:38-42.
19. MDS 2.0 public quality indicator and resident reports. Overview. US Department of Health & Human Services 2009, 11-16. Centers for Medicare & Medicaid Services.
20. Hornberger J., Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006, 145(5):317-325.
21. Pellissier J.M., Brisson M., Levin M.J. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007, 25(49):8326-8337.
22. Rothberg M.B., Virapongse A., Smith K.J. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007, 44(10):1280-1288.
23. Patel M.S., Gebremariam A., Davis M.M. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infect Control Hosp Epidemiol 2008, 29(12):1157-1163.
24. McCullagh P., Nelder J.A. Generalized Linear Models 1989, Chapman and Hall, London. 2nd ed.
25. Agresti A. Categorical Data Analysis 2002, John Wiley & Sons, Hoboken, NJ. 2nd ed.
26. Stein A.N., Britt H., Harrison C., et al. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009, 27(4):520-529.
27. Gauthier A., Breuer J., Carrington D., et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009, 137(1):38-47.
28. Carapetis J.R., Russell D.M., Curtis N. The burden and cost of hospitalised varicella and zoster in Australian children. Vaccine 2004, 23(6):755-761.
29. Schmader K.E., Dworkin R.H. Natural history and treatment of herpes zoster. JPain 2008, 9(1 Suppl. 1):S3-S9.
30. Schmader K., Gnann J.W., Watson C.P. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. JInfect Dis 2008, 197(Suppl 2):S207-S215.